Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study

Authors: RIBEIRO, CAROLINE - Sao Paulo State University (UNESP); RAMOS, FERNANDA - Sao Paulo State University (UNESP); Manthey, John; CESAR, THAIS - Sao Paulo State University (UNESP)

Submitted to: Phytotherapy Research
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 4/20/2019
Publication Date: 6/11/2019
Citation: Ribeiro, C.B., Ramos, F.M., Manthey, J.A., Cesar, T.B. 2019. Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study. Phytotherapy Research. pg. 1-13. https://doi.org/10.1002/ptr.6386.
DOI: https://doi.org/10.1002/ptr.6386

Interpretive Summary: A combination of compounds in lemon was tested in prediabetic individuals to ascertain the effects of this combination of the metabolic markers in these individuals. Treatments at all doses, from 200 to 800 mg produced similar symptom decreases. Short-term intervention with Eriomin, at doses of 200, 400, or 800 mg/day, benefited glycemic control, reduced systemic inflammation and oxidative stress, and reversed the prediabetic condition in 24% of the evaluated patients.

Technical Abstract: This study evaluated the potential effectiveness of different doses of Eriomin® on hyperglycemia and insulin resistance associated with other metabolic biomarkers in prediabetic individuals. Prediabetes patients (n = 103, 49 ± 10 years) were randomly divided into four parallel groups: (a) Placebo; (b) Eriomin 200 mg; (c) Eriomin 400 mg; and (d) Eriomin 800 mg. Assessment of biochemical, metabolic, inflammatory, hepatic, renal, anthropometric markers, blood pressure, and dietary parameters were performed during 12 weeks of intervention. Treatment with all doses of Eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (-5%), insulin resistance (-7%), glucose intolerance (-7%), glycated hemoglobin (-2%), glucagon (-6.5%), C-peptide (-5%), hsCRP (-12%), interleukin-6 (-13%), TNFa (-11%), lipid peroxidation (-17%), systolic blood pressure (-8%), GLP- 1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%). Eriomin or placebo did not influence the anthropometric and dietary variables. Short-term intervention with Eriomin, at doses of 200, 400, or 800 mg/day, benefited glycemic control, reduced systemic inflammation and oxidative stress, and reversed the prediabetic condition in 24% of the evaluated patients.